Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 2Phase 3 2Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1

Conditions

Neoplasm Metastasis 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Interventional × Fluid Therapy × Clear all
NCT04659616 2025-12-19

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

OHSU Knight Cancer Institute

Phase 1 Recruiting
32 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00667485 2014-01-17

Rapamycin Plus Bevacizumab in Advanced Cancers

University of Chicago

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡